Cash Flow

v3.25.2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Cash flows from operating activities    
Net loss from operations $ (13,684,209) $ (23,658,438)
Adjustments to reconcile net loss from continuing operations to net cash (used in) provided by operating activities:    
Depreciation and amortization 757,758 3,678,786
Unrealized (gain) loss on digital assets (101,332) 0
Digital asset revenue (985,009) 0
Gain on the sale of VitaMedica and income from discontinued operations 0 (1,948,538)
Loss on the sale of New England Technology 0 1,737,326
Amortization of loan costs 30,462 115,787
Amortization of consideration discount 0 1,112,676
Impairment of goodwill and intangible assets 0 7,869,425
Inventory write-offs 748,874 1,812,319
Loss on impairment of building 0 336,434
Loss on sale of assets related to relocation of facility 0 569,195
Gain on sale of interactive offers 0 (237,670)
Loss on the disposal of assets 10,743 0
Bad debt reserve for Amazon receivable 933,950 0
Reduction of acquisition payable (152,500) 0
Issuance of stock for services 250,000 0
Lease impairment (gain on settlement) (269,994) 0
Change in deferred tax asset 0 (344,802)
Stock based compensation 2,106,862 1,169,843
Changes in assets and liabilities, net of acquired amounts    
Accounts receivable (484,580) 675,709
Inventory (470,188) 2,651,252
Prepaid expenses and other assets 222,005 106,611
Operating lease payable 20,965 302,050
Accounts payable and accrued liabilities 2,865,251 (944,020)
Deferred revenue (222,100) 101,305
Net cash provided by operating activities - Continuing Operations (8,423,042) (4,894,750)
Net cash provided by (used in) operating activities - Discontinued Operations 0 4,793,374
Net cash provided by operating activities (8,423,042) (101,376)
Cash flows from investing activities    
Proceeds from the sale of the building, net 4,005,516 0
Proceeds from the sale of VitaMedica, Inc. 0 2,100,000
Proceeds from the sale of E-core 2,000,000 0
Proceeds from the sale of Interactive Offers, net of liabilities paid 0 203,025
Acquisition and sale of digital assets, net (104,910,839) 0
Acquisition of Cygnet Online LLC, net 0 (539,348)
Acquisition of property and equipment (387,760) (932,565)
Net cash provided by (used in) investing activities - Continuing Operations (99,293,083) 831,112
Net cash (used in) investing activities - Discontinued Operations 0 (4,206,823)
Net cash provided by (used in) investing activities (99,293,083) (3,375,711)
Cash flows from financing activities    
Payment on acquisition notes payable (66,655) (246,761)
Payment on convertible note (150,000) 0
Proceeds from issuance of short-term debt 20,000,000 0
Proceeds from warrant exercise 250,000 0
Proceeds from issuance of stock 92,556,053 0
Issuance of preferred stock series A 325,000 0
Repayment of related party advance (175,000) 0
Proceeds from related party advance 75,000 100,000
Proceeds from issuance of convertible notes 350,000 0
Repayment of related party note payable (500,000) 0
Repayment on note payable on building (2,634,538) (207,028)
Net cash used in financing activities - Continuing Operations 110,029,860 (353,789)
Net cash (used in) provided by financing activities - Discontinued Operations 0 0
Net cash used in financing activities 110,029,860 (353,789)
Net increase (decrease) in cash - Continuing Operations 2,313,735 (4,417,427)
Net (decrease) increase in cash - Discontinued Operations 0 586,551
Cash, beginning of period 661,415 4,492,291
Cash, end of period 2,975,150 661,415
Supplemental Cash Flow Disclosures    
Interest paid 805,880 839,000
Income tax paid 0 0
Non-cash Investing and Financing Activities    
Issuance of common stock for acquisition of Cygnet 0 162,727
Non-cash proceeds in the sale of VitaMedica 0 1,900,000
Issuance of common stock for the repayment of convertible notes payable 1,750,000 500,000
Issuance of debt for acquisition of Cygnet 0 300,000
Bloomios non-cash payment of receivables, net $ 0 $ 845,443

Source

PDF HTML
ZIP